CODX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
166.1K
+13.8%
146.0K
-44.7%
263.9K
+81.5%
145.4K
-10.8%
162.9K
Cost of Revenue
45.3K
-76.6%
193.8K
+36.1%
142.4K
+441.7%
26.3K
-18.1%
32.1K
Gross Profit
120.8K
+352.7%
-47814
-139.3%
121.5K
+2.0%
119.1K
-9.0%
130.8K
Operating Expenses
6.3M
-31.0%
9.2M
-65.6%
26.7M
+273.8%
7.1M
-12.9%
8.2M
R&D
4.2M
-30.0%
5.9M
+16.4%
5.1M
+13.8%
4.5M
-4.4%
4.7M
SG&A
2.0M
-33.8%
3.0M
+23.0%
2.4M
+1.2%
2.4M
-25.7%
3.2M
Operating Income
-6200783
+32.7%
-9208411
+65.3%
-26541784
-278.4%
-7013848
+13.0%
-8057764
EBITDA
-5998943
+33.0%
-8952966
-21.1%
-7392218
-9.6%
-6746465
+13.1%
-7766350
Net Income
-6283786
+31.2%
-9140038
+64.5%
-25745725
-337.3%
-5886823
+23.8%
-7730117
EPS (Basic)
$-1.46
+64.0%
$-4.06
$-4.80
+31.4%
$-7.00
EPS (Diluted)
$-1.46
+64.0%
$-4.06
$-4.80
+31.4%
$-7.00
Shares (Diluted)
4.3M
+91.3%
2.3M
1.3M
+14.4%
1.1M
Co-Diagnostics (CODX) — Financials